Non Small Cell Lung Cancer Clinical Trials

205 studies are recruiting for non small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Houston, Texas 84 New York, New York 68 Fairfax, Virginia 52 Nashville, Tennessee 51 Boston, Massachusetts 45 Los Angeles, California 43 Chicago, Illinois 29 St Louis, Missouri 28 Dallas, Texas 27 Seattle, Washington 27 San Antonio, Texas 26 Cleveland, Ohio 25 Philadelphia, Pennsylvania 25 Tampa, Florida 24 Baltimore, Maryland 23 Columbus, Ohio 23 Portland, Oregon 23 Salt Lake City, Utah 23 Jacksonville, Florida 22 Pittsburgh, Pennsylvania 22 Atlanta, Georgia 21 Detroit, Michigan 20 Grand Rapids, Michigan 19 La Jolla, California 19 Miami, Florida 19 New Haven, Connecticut 19 Orlando, Florida 19 Rochester, Minnesota 18 Duarte, California 17 Austin, Texas 16 Orange, California 16 San Francisco, California 16 Washington D.C., District of Columbia 16 Aurora, Colorado 15 Cincinnati, Ohio 15 Irvine, California 15 Birmingham, Alabama 14 Omaha, Nebraska 14 Denver, Colorado 13 Indianapolis, Indiana 13 Santa Monica, California 13 Basking Ridge, New Jersey 12 Beverly Hills, California 12 Commack, New York 12 Durham, North Carolina 12 Middletown, New Jersey 12 Milwaukee, Wisconsin 12 Montvale, New Jersey 12 Orange City, Florida 12 Reno, Nevada 12 Sacramento, California 12 St. Petersburg, Florida 12 Bethesda, Maryland 11 Harrison, New York 11 Iowa City, Iowa 11 Louisville, Kentucky 11 Memphis, Tennessee 11 Newport Beach, California 11 Oklahoma City, Oklahoma 11 The Bronx, New York 11

Studies, page 9

  1. Test-retest Evaluation of [18F]F-AraG PET

    This pilot study aims to evaluate the test-retest variability of [18F]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of [18F]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Iowa Hospitals and Clinics, Iowa City, Iowa
    Run by
    CellSight Technologies, Inc.

    See if you can join NCT06084806 on ClinicalTrials.gov

  2. Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

    This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determ…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    HonorHealth Research Institute, Scottsdale, Arizona
    Locations
    3 in total
    Run by
    BioEclipse Therapeutics

    See if you can join NCT04282044 on ClinicalTrials.gov

  3. Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

    The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Baylor Scott and White Research Institute, Dallas, Texas
    Run by
    OncoHost Ltd.

    See if you can join NCT05736029 on ClinicalTrials.gov

  4. I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

    I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of avai…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Chicago, Chicago, Illinois
    Locations
    4 in total
    Run by
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    See if you can join NCT05537922 on ClinicalTrials.gov

  5. First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

    This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. Th…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
    Run by
    A&G Pharmaceutical Inc.

    See if you can join NCT05627960 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.